Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

[1] Beck TM(1999)ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery Am J Health Syst Pharm 56 729-764

[2] Hesketh PH(1992)Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting J Clin Oncol 10 1969-1975

[3] Madajewicz S(2003)Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects Clin Ther 25 1407-1419

[4] Blum RA(2003)Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting Cancer 97 2290-2300

[5] Majumdar A(2001)Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis Eur J Cancer 37 835-842

[6] McCrea J(2007)Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings Support Care Cancer 15 497-503

[7] Chawla SP(2005)Health care provider perception of nausea and vomiting and patients’ reported incidence: the Venezuela Emesis Registry Support Care Cancer 13 414-415

[8] Grunberg SM(2003)Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics Br J Cancer 88 182-187

[9] Gralla RJ(2003)Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 1473-1482

[10] Cocquyt V(2006)Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed Curr Med Res Opin 22 2403-2410

[1] Beck TM(1999)ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery Am J Health Syst Pharm 56 729-764

[2] Hesketh PH(1992)Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting J Clin Oncol 10 1969-1975

[3] Madajewicz S(2003)Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects Clin Ther 25 1407-1419

[4] Blum RA(2003)Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting Cancer 97 2290-2300

[5] Majumdar A(2001)Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis Eur J Cancer 37 835-842

[6] McCrea J(2007)Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings Support Care Cancer 15 497-503

[7] Chawla SP(2005)Health care provider perception of nausea and vomiting and patients’ reported incidence: the Venezuela Emesis Registry Support Care Cancer 13 414-415

[8] Grunberg SM(2003)Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics Br J Cancer 88 182-187

[9] Gralla RJ(2003)Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 1473-1482

[10] Cocquyt V(2006)Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed Curr Med Res Opin 22 2403-2410